Ocugen

Ocugen (NASDAQ: OCGN) is a Malvern, Pennsylvania-based biopharmaceutical company (founded 2013) discovering, developing and commercializing gene and cell therapies, biologics and vaccines, with a focus on inherited retinal diseases. Its modifier gene therapy candidates are OCU400, in Phase 3 for retinitis pigmentosa (and Phase 1/2 for Leber congenital amaurosis); OCU410, in Phase 3 for geographic atrophy secondary to dry age-related macular degeneration after FDA alignment on a pivotal pathway; and OCU410ST, in the Phase 2/3 GARDian3 trial for Stargardt disease — where a September 2026 interim analysis of 26 participants showed a negative treatment effect and the Data Monitoring Committee recommended modifying the study. Earlier-stage assets include OCU200, a recombinant fusion protein for diabetic macular edema, diabetic retinopathy and wet AMD, and NeoCart, an autologous chondrocyte-derived neocartilage for knee cartilage repair. The company is also developing OCU500 (COVID-19), OCU510 (seasonal quadrivalent flu) and OCU520 (combination flu/COVID-19) vaccine candidates, with an NIAID collaboration for OCU500 and a manufacturing partnership with CanSino Biologics.